去纤维钠对肝小静脉闭塞病患者有效果吗？

(Defitelio) is a single-stranded oligonucleotide mixture with anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide sodium is a safe and effective drug for preventing and treating hepatic veno-occlusive disease. It not only has anticoagulant effects, but also promotes fibrinolysis and anti-inflammatory effects.

The application of defibrinated sodium in the treatment of hepatic veno-occlusive disease was first explored abroad. This study included 19 patients. The dose of defibrinated sodium is 5 to 60 mg/kg per day, intravenous infusion, and the median use time is 15 days (2 to 61 days). The results showed that 42% of patients achieved complete remission (CR), and the overall survival (OS) rate 100 days after transplantation reached 32%, and the patients could tolerate defibrinated sodium well. Since then, many clinical trials have confirmed the effectiveness of defibrotide in the treatment of hepatic veno-occlusive disease.

A clinical trial in Europe studied 40 patients with hepatic veno-occlusive disease. The median age of the patients was 30 years old (1-64 years old). The dose of defibrotide sodium was 200.3600 mg/d or 10-40 mg/kg per day, intravenous infusion. The median use time was 18 days (2-71 days). The results showed that the CR rate was 55% and the OS rate 100 days after transplantation was 43%.

Another study included 88 patients with hepatic veno-occlusive disease, with a median age of 35 years (8 months to 62 years). They were treated with defibrotide sodium alone. The dose of defibrotide sodium was 5-60 mg/kg per day, intravenous infusion, and the median use time was 15 days (1-139 days). The results showed that the CR rate was 36%, and the OS rate 100 days after transplantation was 35%. The dose of defibrinated sodium (Defitelio) for most patients who were effective in treatment was 20 to 40 mg/kg per day.

It can be seen that it is still effective for patients with hepatic veno-occlusive disease.

Recommended hot articles: /newsDetail/78477.html